{
  "symbol": "BCDA",
  "company_name": "Biocardia Inc",
  "ir_website": "https://www.biocardia.com/investors/investor-information/id/1041",
  "structured_data": [
    {
      "section_name": "Press Releases",
      "links": [
        {
          "title": "Press releases",
          "url": "https://www.biocardia.com/investors/press-releases/id/20",
          "content": "[Skip to content](#content)\n\n[](https://www.facebook.com/BioCardia-Inc-112652606057053/ \"Facebook\")[](https://www.youtube.com/user/biocardia \"Youtube\")[](https://twitter.com/biocardia_inc \"Twitter\")[](https://www.linkedin.com/company/biocardia/ \"LinkedIn\")\n\n  * info@biocardia.com\n  * [ : (800) 624-1179](#)\n\n\n\n[ ![](/BioCardia/assets/images/logo_new.jpg) ](/ \"Consultancy\")\n\n[_Subscribe e-news_](#) [](#)\n\nNewsLetter :\n\n  * [About Us](/biocardia/about-us/id/7)\n    * [About BioCardia](/about-us/about-biocardia/id/1008)\n    * [Management Team](/about-us/management-team/id/13)\n    * [Board of Directors](/about-us/board-of-directors/id/1018)\n    * [Careers](/about-us/careers/id/1020)\n  * [Pipeline](/biocardia/pipeline/id/4)\n    * [Pipeline Overview](/pipeline/pipeline-overview/id/1039)\n    * [CardiAMP Autologous Cell Therapy](/pipeline/cardiamp-autologous-cell-therapy/id/8)\n    * [CardiALLO and PulmALLO Allogeneic Cell Therapies](/pipeline/cardiallo-and-pulmallo-allogeneic-cell-therapies/id/1002)\n    * [Helix Biotherapeutic Delivery System](/pipeline/helix-biotherapeutic-delivery-system/id/5004)\n    * [Morph DNA and Avance Steerable Introducers](/pipeline/morph-dna-and-avance-steerable-introducers/id/5005)\n  * [Investors](/investors/id/6)\n    * [Investor Information](/investors/investor-information/id/1041)\n    * [Press releases](/investors/press-releases/id/20)\n    * [In the News](/investors/in-the-news/id/21)\n    * [Presentations & Events](/investors/presentations-events/id/1036)\n    * [Financials & Filings](/investors/financials-filings/id/1021)\n    * [Corporate Governance](/investors/corporate-governance/id/1029)\n  * [Science](/biocardia/science/id/5)\n    * [Mechanism of Action](/science/mechanism-of-action/id/1035)\n    * [Scientific Publications](/scientificpubs)\n  * [Contact Us](/contact-us/id/19)\n\n\n\n# PRESS RELEASES\n\n  * [Investor Information](/investors/investor-information/id/1041)\n  * [Press releases](/investors/press-releases/id/20)\n  * [In the News](/investors/in-the-news/id/21)\n  * [Presentations & Events](/investors/presentations-events/id/1036)\n  * [Financials & Filings](/investors/financials-filings/id/1021)\n  * [Corporate Governance](/investors/corporate-governance/id/1029)\n\n\n\nShortcuts [2024](#2024) [2023](#2023) [2022](#2022)\n\n### 2024\n\n  * [BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results](/investors/press-releases/id/1037?pressReleaseId=207)\n\n  * [BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024](/investors/press-releases/id/1037?pressReleaseId=206)\n\n  * [BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure ](/investors/press-releases/id/1037?pressReleaseId=205)\n\n  * [BioCardia Regains Full Compliance with Nasdaq Listing Requirements](/investors/press-releases/id/1037?pressReleaseId=204)\n\n  * [BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules](/investors/press-releases/id/1037?pressReleaseId=203)\n\n  * [BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules](/investors/press-releases/id/1037?pressReleaseId=202)\n\n  * [BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family](/investors/press-releases/id/1037?pressReleaseId=201)\n\n  * [FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment ](/investors/press-releases/id/1037?pressReleaseId=200)\n\n  * [BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results](/investors/press-releases/id/1037?pressReleaseId=199)\n\n  * [BioCardia to Host Q2 2024 Corporate Update and Financial Results Conference Call on August 13, 2024](/investors/press-releases/id/1037?pressReleaseId=198)\n\n  * [BioCardia Submits for FDA Approval of Morph® DNA™ Steerable Introducer Product Family](/investors/press-releases/id/1037?pressReleaseId=197)\n\n  * [Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure ](/investors/press-releases/id/1037?pressReleaseId=196)\n\n  * [BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application](/investors/press-releases/id/1037?pressReleaseId=195)\n\n  * [CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes™ for the Treatment of Acute Myocardial Infarction](/investors/press-releases/id/1037?pressReleaseId=194)\n\n  * [BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach ](/investors/press-releases/id/1037?pressReleaseId=193)\n\n  * [BioCardia Announces Reverse Stock Split](/investors/press-releases/id/1037?pressReleaseId=192)\n\n  * [BioCardia Reports First Quarter 2024 Business Highlights and Financial Results](/investors/press-releases/id/1037?pressReleaseId=191)\n\n  * [BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024](/investors/press-releases/id/1037?pressReleaseId=190)\n\n  * [BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes](/investors/press-releases/id/1037?pressReleaseId=189)\n\n  * [BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort ](/investors/press-releases/id/1037?pressReleaseId=188)\n\n  * [BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results](/investors/press-releases/id/1037?pressReleaseId=187)\n\n  * [BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024](/investors/press-releases/id/1037?pressReleaseId=186)\n\n  * [BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership](/investors/press-releases/id/1037?pressReleaseId=185)\n\n  * [BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study ](/investors/press-releases/id/1037?pressReleaseId=184)\n\n  * [BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure](/investors/press-releases/id/1037?pressReleaseId=182)\n\n  * [BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA](/investors/press-releases/id/1037?pressReleaseId=181)\n\n  * [BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference](/investors/press-releases/id/1037?pressReleaseId=180)\n\n  * [BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders](/investors/press-releases/id/1037?pressReleaseId=179)\n\n\n\n\n### 2023\n\n  * [BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction ](/investors/press-releases/id/1037?pressReleaseId=178)\n\n  * [ BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes](/investors/press-releases/id/1037?pressReleaseId=177)\n\n  * [BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval](/investors/press-releases/id/1037?pressReleaseId=176)\n\n  * [BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules](/investors/press-releases/id/1037?pressReleaseId=175)\n\n  * [BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure](/investors/press-releases/id/1037?pressReleaseId=174)\n\n  * [BioCardia Reports Third Quarter 2023 Business Highlights and Financial Results](/investors/press-releases/id/1037?pressReleaseId=173)\n\n  * [BioCardia to Host Q3 2023 Corporate Update and Financial Results Conference Call on November 8, 2023](/investors/press-releases/id/1037?pressReleaseId=172)\n\n  * [BioCardia Announces Completion of Enrollment in Phase III CardiAMP HF Trial and Plans for CardiAMP HF Trial II](/investors/press-releases/id/1037?pressReleaseId=171)\n\n  * [BioCardia Announces Clarification and Next Steps on its Autologous CardiAMP Cell Therapy Programs](/investors/press-releases/id/1037?pressReleaseId=170)\n\n  * [BioCardia Announces Interim Efficacy Results in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial](/investors/press-releases/id/1037?pressReleaseId=169)\n\n  * [BioCardia Reports Second Quarter 2023 Business Highlights And Financial Results](/investors/press-releases/id/1037?pressReleaseId=168)\n\n  * [BioCardia to Host Q2 2023 Financial Results and Corporate Update Conference Call on August 9, 2023](/investors/press-releases/id/1037?pressReleaseId=167)\n\n  * [BioCardia Announces DSMB Recommendation to Pause New Enrollment in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial While Additional Blinded Data is Collected ](/investors/press-releases/id/1037?pressReleaseId=165)\n\n  * [BioCardia Completes Submission of CardiAMP Cell Therapy System in Heart Failure to Japan’s Pharmaceutical Medical Device Agency](/investors/press-releases/id/1037?pressReleaseId=163)\n\n  * [BioCardia Announces FDA Completes Review of Proposed Adaptive Statistical Analysis Design for Ongoing CardiAMP Cell Therapy in Heart Failure Pivotal Study ](/investors/press-releases/id/1037?pressReleaseId=162)\n\n  * [BioCardia Announces Helix™ Biotherapeutic Delivery Patent Issuance in Japan](/investors/press-releases/id/1037?pressReleaseId=161)\n\n  * [BioCardia Announces Timing of the Next Data Safety Monitoring Board Meeting for the CardiAMP Cell Therapy in Heart Failure Pivotal Study ](/investors/press-releases/id/1037?pressReleaseId=160)\n\n  * [BioCardia Reports First Quarter 2023 Business Highlights and Financial Results](/investors/press-releases/id/1037?pressReleaseId=159)\n\n  * [BioCardia Announces US Patent on Bone Marrow Derived Neurokinin-1 Receptor Positive (NK1R+) Mesenchymal Stem Cells for Therapeutic Applications](/investors/press-releases/id/1037?pressReleaseId=158)\n\n  * [BioCardia to Host Q1 2023 Financial Results and Corporate Update Conference Call on May 10, 2023](/investors/press-releases/id/1037?pressReleaseId=157)\n\n  * [BioCardia Presentations at Next Generation Cardiovascular Drug Development Summit Now Available ](/investors/press-releases/id/1037?pressReleaseId=156)\n\n  * [BioCardia Announces Issuance of Two Patents Related to Technology That Guides Interventional Therapies](/investors/press-releases/id/1037?pressReleaseId=155)\n\n  * [BioCardia Reports Fourth Quarter and Full Year 2022 Business Highlights and Financial Results](/investors/press-releases/id/1037?pressReleaseId=154)\n\n  * [BioCardia to Host 2022 Financial Results and Corporate Update Conference Call on March 29, 2023](/investors/press-releases/id/1037?pressReleaseId=153)\n\n  * [Positive Echocardiography Data from BioCardia Phase III CardiAMP Cell Therapy Heart Failure Trial Presented at American College of Cardiology Annual Meeting](/investors/press-releases/id/1037?pressReleaseId=152)\n\n  * [BioCardia and CellProthera Enhance Collaboration for Development of ProtheraCytes™ for the Treatment of Acute Myocardial Infarction in Europe and Potential Early Access for Patients](/investors/press-releases/id/1037?pressReleaseId=151)\n\n\n\n\n### 2022\n\n  * [BioCardia Letter to Shareholders](/investors/press-releases/id/1037?pressReleaseId=150)\n\n  * [BioCardia Announces $3.6 Million Private Placement of Common Stock](/investors/press-releases/id/1037?pressReleaseId=149)\n\n  * [BioCardia Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure](/investors/press-releases/id/1037?pressReleaseId=148)\n\n  * [BioCardia Reports Third Quarter 2022 Business Highlights and Financial Results](/investors/press-releases/id/1037?pressReleaseId=147)\n\n  * [BioCardia to Host Q3 2022 Financial Results and Corporate Update Conference Call on November 9, 2022](/investors/press-releases/id/1037?pressReleaseId=146)\n\n  * [BioCardia Presents Positive CardiAMP Cell Therapy Heart Failure Trial Two-Year Data at HFSA Annual Meeting ](/investors/press-releases/id/1037?pressReleaseId=145)\n\n  * [CardiAMP Cell Therapy Heart Failure Trial Two Year Roll-In Cohort Data to be Presented at Heart Failure Society of America Annual Meeting ](/investors/press-releases/id/1037?pressReleaseId=144)\n\n  * [BioCardia Announces Participation at H.C. Wainwright Global Investment Conference September 12-14, 2022 (HYBRID CONFERENCE)](/investors/press-releases/id/1037?pressReleaseId=143)\n\n  * [BioCardia to Participate in Cantor Fitzgerald’s Cell and Genetic Medicines Conference ](/investors/press-releases/id/1037?pressReleaseId=142)\n\n  * [BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial](/investors/press-releases/id/1037?pressReleaseId=141)\n\n  * [BioCardia Enters Agreement with BlueRock Therapeutics to Provide Enabling Catheter Biotherapeutic Delivery Product Candidates for BlueRock’s Cell Therapy to Treat Heart Failure](/investors/press-releases/id/1037?pressReleaseId=140)\n\n  * [BioCardia Reports Second Quarter 2022 Business Highlights and Financial Results](/investors/press-releases/id/1037?pressReleaseId=139)\n\n  * [BioCardia to Host Q2 2022 Financial Results and Corporate Update Conference Call on August 10, 2022](/investors/press-releases/id/1037?pressReleaseId=138)\n\n  * [BioCardia Announces First Canadian Clinical Site for CardiAMP Cell Therapy Heart Failure Trial](/investors/press-releases/id/1037?pressReleaseId=137)\n\n  * [BioCardia to Participate in Upcoming Heart and Pulmonary Therapy Development Symposia](/investors/press-releases/id/1037?pressReleaseId=136)\n\n  * [BioCardia Announces US Patent on Imaging System for Targeting Cardiac Therapies](/investors/press-releases/id/1037?pressReleaseId=135)\n\n  * [BioCardia Reports First Quarter 2022 Business Highlights and Financial Results](/investors/press-releases/id/1037?pressReleaseId=130)\n\n  * [BioCardia to Host Q1 2022 Financial Results and Corporate Update Conference Call on May 11, 2022](/investors/press-releases/id/1037?pressReleaseId=129)\n\n  * [BioCardia Announces FDA Approval of Its IND for NK1R+ Mesenchymal Stem Cells for the Treatment of Patients Recovering from Acute Respiratory Distress due to COVID-19](/investors/press-releases/id/1037?pressReleaseId=128)\n\n  * [BioCardia Reports 2021 Financial Results and Recent Business Highlights](/investors/press-releases/id/1037?pressReleaseId=127)\n\n  * [BioCardia to Host 2021 Financial Results and Corporate Update Conference Call on March 29, 2022](/investors/press-releases/id/1037?pressReleaseId=126)\n\n  * [BioCardia Announces New Center for Medicare and Medicaid Services Reimbursement Code Applicable to the CardiAMP Cell Therapy Procedure ](/investors/press-releases/id/1037?pressReleaseId=125)\n\n  * [BioCardia Receives No Objection Letter from Health Canada, Enabling Company to Expand CardiAMP Cell Therapy Heart Failure Trial into Canada](/investors/press-releases/id/1037?pressReleaseId=124)\n\n  * [BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Study as Designed](/investors/press-releases/id/1037?pressReleaseId=123)\n\n  * [BioCardia Receives FDA Breakthrough Device Designation for CardiAMP Cell Therapy System for Heart Failure](/investors/press-releases/id/1037?pressReleaseId=122)\n\n  * [BioCardia Announces Participation at the Upcoming Digital Medicine & Medtech Showcase and the H.C. Wainwright BioConnect Virtual Conference](/investors/press-releases/id/1037?pressReleaseId=121)\n\n\n\n\nHave questions?CALL US NOW\n\n: (800) 624-1179\n\nHave questions? EMAIL US NOW\n\n: info@biocardia.com\n\n## Congratulation\n\n#### you have successfully subscribed to our newsletter\n\n[](#)\n"
        }
      ]
    },
    {
      "section_name": "In the News",
      "links": [
        {
          "title": "In the News",
          "url": "https://www.biocardia.com/investors/in-the-news/id/21",
          "content": "[Skip to content](#content)\n\n[](https://www.facebook.com/BioCardia-Inc-112652606057053/ \"Facebook\")[](https://www.youtube.com/user/biocardia \"Youtube\")[](https://twitter.com/biocardia_inc \"Twitter\")[](https://www.linkedin.com/company/biocardia/ \"LinkedIn\")\n\n  * info@biocardia.com\n  * [ : (800) 624-1179](#)\n\n\n\n[ ![](/BioCardia/assets/images/logo_new.jpg) ](/ \"Consultancy\")\n\n[_Subscribe e-news_](#) [](#)\n\nNewsLetter :\n\n  * [About Us](/biocardia/about-us/id/7)\n    * [About BioCardia](/about-us/about-biocardia/id/1008)\n    * [Management Team](/about-us/management-team/id/13)\n    * [Board of Directors](/about-us/board-of-directors/id/1018)\n    * [Careers](/about-us/careers/id/1020)\n  * [Pipeline](/biocardia/pipeline/id/4)\n    * [Pipeline Overview](/pipeline/pipeline-overview/id/1039)\n    * [CardiAMP Autologous Cell Therapy](/pipeline/cardiamp-autologous-cell-therapy/id/8)\n    * [CardiALLO and PulmALLO Allogeneic Cell Therapies](/pipeline/cardiallo-and-pulmallo-allogeneic-cell-therapies/id/1002)\n    * [Helix Biotherapeutic Delivery System](/pipeline/helix-biotherapeutic-delivery-system/id/5004)\n    * [Morph DNA and Avance Steerable Introducers](/pipeline/morph-dna-and-avance-steerable-introducers/id/5005)\n  * [Investors](/investors/id/6)\n    * [Investor Information](/investors/investor-information/id/1041)\n    * [Press releases](/investors/press-releases/id/20)\n    * [In the News](/investors/in-the-news/id/21)\n    * [Presentations & Events](/investors/presentations-events/id/1036)\n    * [Financials & Filings](/investors/financials-filings/id/1021)\n    * [Corporate Governance](/investors/corporate-governance/id/1029)\n  * [Science](/biocardia/science/id/5)\n    * [Mechanism of Action](/science/mechanism-of-action/id/1035)\n    * [Scientific Publications](/scientificpubs)\n  * [Contact Us](/contact-us/id/19)\n\n\n\n# IN THE NEWS\n\n  * [Investor Information](/investors/investor-information/id/1041)\n  * [Press releases](/investors/press-releases/id/20)\n  * [In the News](/investors/in-the-news/id/21)\n  * [Presentations & Events](/investors/presentations-events/id/1036)\n  * [Financials & Filings](/investors/financials-filings/id/1021)\n  * [Corporate Governance](/investors/corporate-governance/id/1029)\n\n\n\nShortcuts [2024](#2024) [2022](#2022) [2021](#2021) [2020](#2020)\n\n### 2024\n\n  * Article on Partner CellProthera [Read More](https://www.drugdiscoverynews.com/a-cell-therapy-to-heal-a-broken-heart-15962)\n\n  * ![](/media/news/45/TCT_MD_logo.JPG)\n\nTCT MD Small Study Hints at Potential for HF Bone Marrow Cell Therapy: CardiAMP-HF [Read More](https://www.tctmd.com/news/small-study-hints-potential-hf-bone-marrow-cell-therapy-cardiamp-hf)\n\n\n\n\n### 2022\n\n  * ![](/media/news/44/Fierce_Biotech.jpg)\n\nFierce Biotech BioCardia's off-the-shelf cell therapy for heart failure to enter first-in-human study [Read More](https://www.fiercebiotech.com/medtech/biocardias-shelf-cell-therapy-heart-failure-enter-first-human-study)\n\n\n\n\n### 2021\n\n  * ![](/media/news/43/empowered_patient_logo.jpg)\n\nEmpowered Patient Podcast Optimizing Autologous Cell Therapy to Treat Cardiovascular Disease with Dr. Peter Altman [Read More](https://empoweredpatientradio.com/optimizing-autologous-cell-therapy-to-treat-cardiovascular-disease-with-dr-peter-altman-biocardia)\n\n  * ![](/media/news/40/logo_news_uw_smph.jpg)\n\nUW Health UW Health Treats First Patient in U.S. with Investigational Cell Therapy for Heart Disease [Read More](https://www.med.wisc.edu/news-and-events/2021/october/patient-first-to-receive-new-heart-disease-therapy/)\n\n  * ![](/media/news/41/logo_news_greenbay_cbs.jpg)\n\nGreenbay CBS Neenah musician, educator pursues dream after being first in the world to undergo ‘Investigational Cell Therapy’ [Read More](https://www.wearegreenbay.com/news/local-news/local-neenah-musician-and-educator-is-the-first-in-the-world-to-undergo-investigational-cell-therapy-to-treat-heart-disease/)\n\n  * ![](/media/news/42/logo_news_wbay2.jpg)\n\nWBay.com Neenah man gets new lease on life after trial heart procedure [Read More](https://www.wbay.com/2021/10/29/neenah-man-gets-new-lease-life-after-trial-heart-procedure/)\n\n  * ![](/media/news/39/logo_news_henryford.jpg)\n\nHenry Ford Health System Henry Ford Health System Studies Novel Cell Therapy Aimed at Improving Heart Failure Symptoms [Read More](https://www.henryford.com/news/2021/03/cardiamp)\n\n  * ![](/media/news/38/cell&gene_logo.jpg)\n\nCell & Gene Inside BioCardia's CardiAMP Cell Therapy [Read More](https://www.cellandgene.com/doc/inside-biocardia-s-cardiamp-cell-therapy-0001)\n\n\n\n\n### 2020\n\n  * ![](/media/news/36/logo_news_biotuesdays.jpg)\n\nBioTuesdays BioCardia developing autologous and allogenic cardiovascular cell therapies [Read More](https://biotuesdays.com/2020/09/15/biocardia-developing-autologous-and-allogenic-cardiovascular-cell-therapies/)\n\n  * ![](/media/news/34/logo_news_pharma_tech.jpg)\n\nPharmaceutical Technology BioCardia’s novel CardiAMP stem cell therapy closer to approval in heart failure [Read More](https://www.pharmaceutical-technology.com/comment/biocardia-stem-cell-therapy-heart-failure/)\n\n\n\n\nHave questions?CALL US NOW\n\n: (800) 624-1179\n\nHave questions? EMAIL US NOW\n\n: info@biocardia.com\n\n## Congratulation\n\n#### you have successfully subscribed to our newsletter\n\n[](#)\n"
        }
      ]
    },
    {
      "section_name": "Presentations & Events",
      "links": [
        {
          "title": "Presentations & Events",
          "url": "https://www.biocardia.com/investors/presentations-events/id/1036",
          "content": "[Skip to content](#content)\n\n[](https://www.facebook.com/BioCardia-Inc-112652606057053/ \"Facebook\")[](https://www.youtube.com/user/biocardia \"Youtube\")[](https://twitter.com/biocardia_inc \"Twitter\")[](https://www.linkedin.com/company/biocardia/ \"LinkedIn\")\n\n  * info@biocardia.com\n  * [ : (800) 624-1179](#)\n\n\n\n[ ![](/BioCardia/assets/images/logo_new.jpg) ](/ \"Consultancy\")\n\n[_Subscribe e-news_](#) [](#)\n\nNewsLetter :\n\n  * [About Us](/biocardia/about-us/id/7)\n    * [About BioCardia](/about-us/about-biocardia/id/1008)\n    * [Management Team](/about-us/management-team/id/13)\n    * [Board of Directors](/about-us/board-of-directors/id/1018)\n    * [Careers](/about-us/careers/id/1020)\n  * [Pipeline](/biocardia/pipeline/id/4)\n    * [Pipeline Overview](/pipeline/pipeline-overview/id/1039)\n    * [CardiAMP Autologous Cell Therapy](/pipeline/cardiamp-autologous-cell-therapy/id/8)\n    * [CardiALLO and PulmALLO Allogeneic Cell Therapies](/pipeline/cardiallo-and-pulmallo-allogeneic-cell-therapies/id/1002)\n    * [Helix Biotherapeutic Delivery System](/pipeline/helix-biotherapeutic-delivery-system/id/5004)\n    * [Morph DNA and Avance Steerable Introducers](/pipeline/morph-dna-and-avance-steerable-introducers/id/5005)\n  * [Investors](/investors/id/6)\n    * [Investor Information](/investors/investor-information/id/1041)\n    * [Press releases](/investors/press-releases/id/20)\n    * [In the News](/investors/in-the-news/id/21)\n    * [Presentations & Events](/investors/presentations-events/id/1036)\n    * [Financials & Filings](/investors/financials-filings/id/1021)\n    * [Corporate Governance](/investors/corporate-governance/id/1029)\n  * [Science](/biocardia/science/id/5)\n    * [Mechanism of Action](/science/mechanism-of-action/id/1035)\n    * [Scientific Publications](/scientificpubs)\n  * [Contact Us](/contact-us/id/19)\n\n\n\n# presentations & events\n\n  * [Investor Information](/investors/investor-information/id/1041)\n  * [Press releases](/investors/press-releases/id/20)\n  * [In the News](/investors/in-the-news/id/21)\n  * [Presentations & Events](/investors/presentations-events/id/1036)\n  * [Financials & Filings](/investors/financials-filings/id/1021)\n  * [Corporate Governance](/investors/corporate-governance/id/1029)\n\n\n\n#### Presentations\n\n[Corporate Presentation](/media/Investors/biocardia_corporate_presentation.pdf)\n\n[The Science of CardiAMP Cell Therapy](/media/Investors/presentations_and_events/05141_b_mkt_science_of_cardiamp_cell_therapy.pdf \"The Science of CardiAMP Cell Therapy\")\n\n[CardiAMP and CardiALLO Synergies](/media/Investors/05782-A%28MKT%29%20CardiAMP%20and%20CardiALLO%20Synergies.pdf \"CardiAMP and CardiALLO Synergies\")[Constructing a Selection Biomarker Panel](/media/Investors/05783_a_mkt_constructing_a_selection_biomarker_panel_final.pdf \"Constructing a Selection BioMarker Panel\")[April 30, 2024 Conference call presentation](/media/Investors/cardiamp_cmi_roll_in_cohort_webcast_slides_04_30_24.pdf)\n\n#### Upcoming Events\n\n###### **Q3 2024 Corporate Update and Financial Results Conference Call - November 13, 2024**\n\nParticipants can register for the conference by navigating to <https://dpregister.com/sreg/10194429/fdf5f0e427>. Please note that registered participants will receive their dial-in number upon registration. For those who have not registered,to listen to the call by phone, interested parties within the U.S. should call 1-833-316-0559 and international callers should call 1-412-317-5730. All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the BioCardia call. The conference call will also be available through a live webcast, which can be accessed through the following link: <https://event.choruscall.com/mediaframe/webcast.html?webcastid=fmwk6hNm>.\n\nA webcast replay of the call will be available approximately one hour after the end of the call through November 27, 2024 at the following link: <https://services.choruscall.com/ccforms/replay.html>. A telephonic replay of the call will also be available through November 27, 2024 and may be accessed by calling 1-877-344-7529 (domestic), 1-412-317-0088 (international) or 855-669-9658 (Canada) by using access code 6220156.**We will be attending scientific sessions at:** American Heart Association 2024Technology and Heart Failure Therapeutics 2025American College of Cardiology 2025International Society for Heart and Lung Transplantation 2025\n\n#### Past Events\n\n###### BioCardia Q2 2024 Corporate Update and Financial Results Conference Call from August 13, 2024\n\nCorporate update and report of out financial results for the three months ended June 30, 2024.\n\nA webcast replay of the call will be available approximately one hour after the end of the call at the following link:<https://services.choruscall.com/ccforms/replay.html>. A telephonic replay of the call will be available and may be accessed by calling 1-877-344-7529 (domestic), 1-412-317-0088 (international) or 855-669-9658 (Canada) by using access code 6578627.\n\n**A.G.P. Virtual Healthcare Company Showcase - May 21, 2024** Dr. Peter Altman to participate in a fireside chat style session from 2:20pm – 2:40pm EST on 5/21 moderated by the A.G.P. team. The presentation will be webcast live on Tuesday, May 21, 2024, at 2:20 p.m. ET. To listen to the event, please click [here](https://us02web.zoom.us/webinar/register/WN_hfErL76eRVquDCCNLXTFDg#/registration) to access the webcast. More details on A.G.P.’s [website ](https://allianceg.com/events/)\n\nHave questions?CALL US NOW\n\n: (800) 624-1179\n\nHave questions? EMAIL US NOW\n\n: info@biocardia.com\n\n## Congratulation\n\n#### you have successfully subscribed to our newsletter\n\n[](#)\n"
        }
      ]
    },
    {
      "section_name": "Financials & Filings",
      "links": [
        {
          "title": "Financials & Filings",
          "url": "https://www.biocardia.com/investors/financials-filings/id/1021",
          "content": "[Skip to content](#content)\n\n[](https://www.facebook.com/BioCardia-Inc-112652606057053/ \"Facebook\")[](https://www.youtube.com/user/biocardia \"Youtube\")[](https://twitter.com/biocardia_inc \"Twitter\")[](https://www.linkedin.com/company/biocardia/ \"LinkedIn\")\n\n  * info@biocardia.com\n  * [ : (800) 624-1179](#)\n\n\n\n[ ![](/BioCardia/assets/images/logo_new.jpg) ](/ \"Consultancy\")\n\n[_Subscribe e-news_](#) [](#)\n\nNewsLetter :\n\n  * [About Us](/biocardia/about-us/id/7)\n    * [About BioCardia](/about-us/about-biocardia/id/1008)\n    * [Management Team](/about-us/management-team/id/13)\n    * [Board of Directors](/about-us/board-of-directors/id/1018)\n    * [Careers](/about-us/careers/id/1020)\n  * [Pipeline](/biocardia/pipeline/id/4)\n    * [Pipeline Overview](/pipeline/pipeline-overview/id/1039)\n    * [CardiAMP Autologous Cell Therapy](/pipeline/cardiamp-autologous-cell-therapy/id/8)\n    * [CardiALLO and PulmALLO Allogeneic Cell Therapies](/pipeline/cardiallo-and-pulmallo-allogeneic-cell-therapies/id/1002)\n    * [Helix Biotherapeutic Delivery System](/pipeline/helix-biotherapeutic-delivery-system/id/5004)\n    * [Morph DNA and Avance Steerable Introducers](/pipeline/morph-dna-and-avance-steerable-introducers/id/5005)\n  * [Investors](/investors/id/6)\n    * [Investor Information](/investors/investor-information/id/1041)\n    * [Press releases](/investors/press-releases/id/20)\n    * [In the News](/investors/in-the-news/id/21)\n    * [Presentations & Events](/investors/presentations-events/id/1036)\n    * [Financials & Filings](/investors/financials-filings/id/1021)\n    * [Corporate Governance](/investors/corporate-governance/id/1029)\n  * [Science](/biocardia/science/id/5)\n    * [Mechanism of Action](/science/mechanism-of-action/id/1035)\n    * [Scientific Publications](/scientificpubs)\n  * [Contact Us](/contact-us/id/19)\n\n\n\n# investors\n\n  * [Investor Information](/investors/investor-information/id/1041)\n  * [Press releases](/investors/press-releases/id/20)\n  * [In the News](/investors/in-the-news/id/21)\n  * [Presentations & Events](/investors/presentations-events/id/1036)\n  * [Financials & Filings](/investors/financials-filings/id/1021)\n  * [Corporate Governance](/investors/corporate-governance/id/1029)\n\n\n\n## Financials & Filings\n\nHave questions?CALL US NOW\n\n: (800) 624-1179\n\nHave questions? EMAIL US NOW\n\n: info@biocardia.com\n\n## Congratulation\n\n#### you have successfully subscribed to our newsletter\n\n[](#)\n"
        }
      ]
    },
    {
      "section_name": "Corporate Governance",
      "links": [
        {
          "title": "Corporate Governance",
          "url": "https://www.biocardia.com/investors/corporate-governance/id/1029",
          "content": "[Skip to content](#content)\n\n[](https://www.facebook.com/BioCardia-Inc-112652606057053/ \"Facebook\")[](https://www.youtube.com/user/biocardia \"Youtube\")[](https://twitter.com/biocardia_inc \"Twitter\")[](https://www.linkedin.com/company/biocardia/ \"LinkedIn\")\n\n  * info@biocardia.com\n  * [ : (800) 624-1179](#)\n\n\n\n[ ![](/BioCardia/assets/images/logo_new.jpg) ](/ \"Consultancy\")\n\n[_Subscribe e-news_](#) [](#)\n\nNewsLetter :\n\n  * [About Us](/biocardia/about-us/id/7)\n    * [About BioCardia](/about-us/about-biocardia/id/1008)\n    * [Management Team](/about-us/management-team/id/13)\n    * [Board of Directors](/about-us/board-of-directors/id/1018)\n    * [Careers](/about-us/careers/id/1020)\n  * [Pipeline](/biocardia/pipeline/id/4)\n    * [Pipeline Overview](/pipeline/pipeline-overview/id/1039)\n    * [CardiAMP Autologous Cell Therapy](/pipeline/cardiamp-autologous-cell-therapy/id/8)\n    * [CardiALLO and PulmALLO Allogeneic Cell Therapies](/pipeline/cardiallo-and-pulmallo-allogeneic-cell-therapies/id/1002)\n    * [Helix Biotherapeutic Delivery System](/pipeline/helix-biotherapeutic-delivery-system/id/5004)\n    * [Morph DNA and Avance Steerable Introducers](/pipeline/morph-dna-and-avance-steerable-introducers/id/5005)\n  * [Investors](/investors/id/6)\n    * [Investor Information](/investors/investor-information/id/1041)\n    * [Press releases](/investors/press-releases/id/20)\n    * [In the News](/investors/in-the-news/id/21)\n    * [Presentations & Events](/investors/presentations-events/id/1036)\n    * [Financials & Filings](/investors/financials-filings/id/1021)\n    * [Corporate Governance](/investors/corporate-governance/id/1029)\n  * [Science](/biocardia/science/id/5)\n    * [Mechanism of Action](/science/mechanism-of-action/id/1035)\n    * [Scientific Publications](/scientificpubs)\n  * [Contact Us](/contact-us/id/19)\n\n\n\n# corporate governance\n\n  * [Investor Information](/investors/investor-information/id/1041)\n  * [Press releases](/investors/press-releases/id/20)\n  * [In the News](/investors/in-the-news/id/21)\n  * [Presentations & Events](/investors/presentations-events/id/1036)\n  * [Financials & Filings](/investors/financials-filings/id/1021)\n  * [Corporate Governance](/investors/corporate-governance/id/1029)\n    * [Committee Composition](/investors/corporate-governance/committee-composition/id/2001)\n\n\n\n## Corporate Governance\n\n  * [Audit Committee Charter](/media/Investors/audit_committee_2020.pdf)\n  * [Code of Business Conduct and Ethics](/media/Investors/code_of_conduct.pdf)\n  * [Compensation Committee Charter](/media/Investors/compensation_committee_2020.pdf)\n  * [Corporate Governance Guidelines](/media/Investors/corporate_governance_guidelines.pdf)\n  * [Nominating and Corporate Governance Committee](/media/Investors/nominating_corporate_governance_2020.pdf)\n  * [Science and Technology Charter](/media/Investors/science_tech_committee_charter_2021.pdf)\n  * [Whistleblower Compliance](/media/Investors/whistleblower_compliance_08272018.pdf)\n\n\n\nHave questions?CALL US NOW\n\n: (800) 624-1179\n\nHave questions? EMAIL US NOW\n\n: info@biocardia.com\n\n## Congratulation\n\n#### you have successfully subscribed to our newsletter\n\n[](#)\n"
        }
      ]
    }
  ]
}